This will lead to an increased confidence in published biomarkers and adoption for successful commercial development of diagnostic tests. Since the return on investment for European life sciences companies will increase, they will be more competitive in the worldwide biomarker diagnostic market. Physicians: The increased number of biomarkers with established reproducible feasibility and new diagnostic tests for these biomarkers will aid physicians to diagnose patients in more detail, allowing personalized treatments and better chances of survival and/or quality of life. This will first be achieved for the demonstrator project of COPD, but later also for other disease indications. Patients: The availability of better biomarkers will improve diagnosis, prognosis, and predict response to treatment of patients at a personal level. As a result, patients will receive personalized treatments, greatly improving their survival and quality of life. European healthcare system: Through improved diagnosis, prognosis, and prediction of response to treatment, patients will receive more effective treatments. This will decrease health cost expenditures. Ultimately, the correct use of reliable biomarkers will both improve healthy outcome throughout Europe and decrease health care expenses.